Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Exela Pharma Sciences LLC
EIR
•Exela Pharma Sciences LLC•December 19, 2018

Exela Pharma Sciences LLC – FDA EIR, Dec 19, 2018

Record Details

An FDA compliance follow-up inspection of Exela Pharma Sciences LLC, a manufacturer of sterile small volume parenteral drug products, was conducted from December 12-19, 2018. The inspection evaluated the company's adherence to Current Good Manufacturing Practices (cGMP) under compliance program 7356.002A, focusing on quality, materials, and production systems, and verifying corrective actions from a previous 2017 inspection.

While the prior inspection resulted in a Form FDA-483 citing deficiencies such as untimely deviation investigations and inadequate identity/integrity testing for manufacturing gases, this current inspection did not result in a new FDA-483 issuance. However, several critical observations were discussed with management for immediate improvement.

Key issues raised included an inoperable HEPA filter in a sterile fill suite for over a year without proper evaluation, improperly labeled non-sterile solution for tools used in aseptic operations, and a lack of continuous monitoring for positive airflow in a critical cleanroom. Concerns also involved a physical gap in a cleanroom material transfer window, undocumented operational challenges for an automated visual inspection machine, and insufficient procedures for the storage and labeling of in-process materials. Furthermore, a raw material had remained in quarantine for over a year due to delayed testing.

Management acknowledged these concerns and committed to addressing them, including repairing/replacing the HEPA filter, ensuring proper labeling and training, implementing continuous airflow monitoring, documenting equipment challenges, formalizing WIP procedures, and discarding the compromised raw material. The agency will further evaluate these discussions for final compliance determination.

Company
Exela Pharma Sciences LLC
Inspection date
December 19, 2018
Product type
Drugs
Office
Office of Pharmaceutical Quality Operations Division I
People
  • John Mazza (company_representative)
  • Baron Bowers (company_representative)
  • Shannon Pride (company_representative)
  • Elizabeth Jolley (company_representative)
  • Gideon N. Esuzor (Investigator)
View Company Profile

ID · 46cd4842-57f4-427d-b5ba-3a0d9b0f1ed1

Other documents for Exela Pharma Sciences LLC
  • WARNING_LETTER - 2024-11-15November 15, 2024
  • 483 - 2024-11-04November 4, 2024
  • EIR - 2019-10-22October 22, 2019
  • EIR - 2019-07-18July 18, 2019
  • 483 - 2019-07-18July 18, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Exela Pharma Sciences LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.